OKYO Pharma Ltd (LSE:OKYO) - Share price - Overview


Stock Report

OKYO Pharma Ltd OKYO

Last Price
GBX1.20

Day Change
0.00|0.00%

As of 26/03/2019
15:23:59 GMT | GBX
Minimum 15 Minutes Delay.

Last Close1.20p
Day Range1.04 - 1.11
Mkt Cap6.29Mil
52-Wk Range1.00 - 8.00
Yield %-
ISINGG00BD3FV870
Volume224,471
P/E-3.97
P/S-
P/CF-0.05

Share Price

Total Returns 25/03/2019

 Chg (%)  
More ...
OKYO Pharma Ltd0.00 
FTSE 100 TR GBP0.44
 
Financials
201620172018
More ...
Income Statement
Turnover---
Operating Profit-0.76-0.29-0.84
Net Profit-0.70-0.19-53.15
Reported EPS-0.18-0.10-14.00
Balance Sheet
Current Assets3.7455.062.01
Non Current Assets18.660.000.00
Total Assets22.4055.062.01
Current Liabilities0.130.170.09
Total Liabilities---
Total Equity22.2754.891.92
Cash Flow
Operating Cash Flow-0.45-0.52-1.00
Net Change in Cash-0.68-0.52-1.00

Company Profile

OKYO Pharma Corp is engaged in the exploration and development of minerals mainly iron ore mining. The Company has an operation in Cameroon at the holding level.

Sector

Biotechnology

Index

Next Event 31/07/2019

Final Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-43.69
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Executive DirectorMr. Willy Jules Simon
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.